NCT07110246View on ClinicalTrials.gov

Dabrafenib and Trametinib for BRAF V600 Mutant Low-Grade Gliomas

PHASE2Not yet recruitingINTERVENTIONAL
Enrollment

96

Participants

Timeline

Start Date

October 1, 2025

Primary Completion Date

December 31, 2031

Study Completion Date

December 31, 2031

Conditions
BRAF V600 MutationLow-grade GliomaLow Grade Glioma of BrainRecurrent Low Grade Glioma
Interventions
DRUG

Dabrafenib

Given orally (PO)

DRUG

Trametinib

Given PO

PROCEDURE

Magnetic Resonance Imaging (MRI)

Undergo imaging by MRI

PROCEDURE

Specimen Collection

Under collection of blood and optional CSF samples

PROCEDURE

Optional Lumbar puncture

Undergo optional lumbar puncture

Trial Locations (1)

94143

Univeristy of California, San Francisco, San Francisco

All Listed Sponsors
collaborator

Rising Tide Foundation

OTHER

lead

University of California, San Francisco

OTHER